Drug intelligence / Profile preview

THOR-212b

Development stage: Preclinical
Lead developer: THOR Biopharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

THOR-212b is a preclinical bispecific monoclonal antibody being developed by THOR Biopharma. It is designed to simultaneously target the RET (Rearranged during Transfection) proto-oncogene and a proprietary, undisclosed target referred to as Target G. The drug is currently in the candidate optimization stage of preclinical development. By engaging both RET and Target G, THOR-212b aims to provide a multi-targeted approach to treating cancers driven by RET alterations, potentially overcoming resistance mechanisms associated with monotherapy.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)Gα (G-protein α subunits)

Beyond the preview

Go deeper on THOR-212b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THOR-212b.

Explore the full profile